Scancell Holdings (FRA:SCP) Operating Income : €-20.66 Mil (TTM As of Oct. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Operating Income?

Scancell Holdings's Operating Income for the six months ended in Oct. 2023 was €-9.37 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Oct. 2023 was €-20.66 Mil.

Warning Sign:

Scancell Holdings PLC has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Scancell Holdings's Operating Income for the six months ended in Oct. 2023 was €-9.37 Mil. Scancell Holdings's Revenue for the six months ended in Oct. 2023 was €0.00 Mil. Therefore, Scancell Holdings's Operating Margin % for the quarter that ended in Oct. 2023 was %.

Scancell Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scancell Holdings's annualized ROC % for the quarter that ended in Oct. 2023 was -142.23%. Scancell Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -154.78%.

Scancell Holdings Operating Income Historical Data

The historical data trend for Scancell Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Operating Income Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Operating Income

Get a 7-Day Free Trial

-7.80

-7.75

-10.23

-15.93

-13.54

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Operating Income	Get a 7-Day Free Trial															-6.37	-9.47	-2.27	-11.30	-9.37

Scancell Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-20.66 Mil.

Scancell Holdings (FRA:SCP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scancell Holdings's annualized ROC % for the quarter that ended in Oct. 2023 is calculated as:

	ROC % (Q: Oct. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Apr. 2023 )	+	Invested Capital (Q: Oct. 2023 ))	/ count )
=	-18.732 * ( 1 - 28.99% )	/	( (10.042	+	8.662)	/ 2 )
=	-13.3015932	/	9.352
=	-142.23 %

where

	Invested Capital		(Q: Apr. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.379	-	1.713	-	( 22.624	-	max(0, 3.721	-	27.946	+	22.624	))
=	10.042

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	25.667	-	1.919	-	( 15.086	-	max(0, 2.272	-	19.619	+	15.086	))
=	8.662

Note: The Operating Income data used here is two times the semi-annual (Oct. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Scancell Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Oct. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Apr. 2023		Q: Oct. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.14	/	( ( (2.554 + max(1.949, 0))	+	(2.109 + max(2.614, 0)) )	/	2 )
=	-7.14	/	( ( 4.503	+	4.723 )	/	2 )
=	-7.14	/	4.613
=	-154.78 %

where Working Capital is:

	Working Capital		(Q: Apr. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.611	+	0	+	4.711)	-	(1.713	+	0	+	1.66)
=	1.949

	Working Capital		(Q: Oct. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.549	+	0	+	3.984)	-	(1.919	+	0	+	-4.4408920985006E-16)
=	2.614

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Oct. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Scancell Holdings's Operating Margin % for the quarter that ended in Oct. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Oct. 2023 )	/	Revenue (Q: Oct. 2023 )
	=	-9.366	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Scancell Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines